Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Capital Expenditures of $34000.0 for Q1 2026, down 81.22% quarter-over-quarter from $181000.0 in Q2 2024.
Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Capital Expenditures history runs 7 years deep, the most recent figure standing at $34000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $34000.0; the TTM figure through Mar 2026 stood at $34000.0 (down 81.22% YoY), while the FY2024 annual figure was $221000.0, down 62.09% from the prior year.
- Capital Expenditures for Q1 2026 stood at $34000.0, down from $181000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $2.3 million in Q3 2022, with the low at -$135000.0 in Q2 2022.
- The 4-year median for Capital Expenditures is $166500.0 (2022), against an average of $338600.0.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures slumped 116.48% in 2022, then surged 336.3% in 2023.
- Zentalis Pharmaceuticals' Capital Expenditures stood at $160000.0 in 2022, then increased by 8.12% to $173000.0 in 2023, then advanced by 4.62% to $181000.0 in 2024, then slumped by 81.22% to $34000.0 in 2026.
- Business Quant data shows ZNTL's Capital Expenditures at $34000.0 in Q1 2026, $181000.0 in Q2 2024, and $40000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Jun 30, 2024 | 181,000.00 |
| Jun 30, 2024 | 181,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | 173,000.00 |
| Dec 31, 2023 | 173,000.00 |
| Sep 30, 2023 | 91,000.00 |
| Sep 30, 2023 | 91,000.00 |
| Jun 30, 2023 | 319,000.00 |
| Jun 30, 2023 | 319,000.00 |
| Dec 31, 2022 | 160,000.00 |
| Dec 31, 2022 | 160,000.00 |
| Sep 30, 2022 | 2.30 Mn |
| Sep 30, 2022 | 2.30 Mn |
| Jun 30, 2022 | -135,000.00 |
| Jun 30, 2022 | -135,000.00 |
| Mar 31, 2022 | 226,000.00 |
| Mar 31, 2022 | 226,000.00 |